On Wednesday, Sanofi reports a 79.5% efficacy for its respiratory syncytial virus (RSV) treatment candidate in infants with lower respiratory tract infections (LRTI), the company has announced in a press release.
The efficacy result has been calculated based on a pooled analysis of data from a phase III and phase IIb.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.